key: cord-0873656-n4ourmsm
authors: Wang, Janice; Hajizadeh, Negin; Shore-Lesserson, Linda
title: The Value of Thromboelastography (TEG) in COVID-19 Critical Illness as Illustrated by a Case Series
date: 2021-10-16
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2021.10.015
sha: 14dd4d34cd2884d1b5374da03bc67970e3f23e28
doc_id: 873656
cord_uid: n4ourmsm

Objective To develop a practical thromboelastograph (TEG) guided anticoagulation protocol to guide the management of COVID-19 critically ill patients. Design An inter-disciplinary team reviewed the current literature on hypercoagulability in COVID-19 critically ill patients, clinical management practices and challenges with high rates of thrombotic events despite anticoagulant therapies. Setting The largest tertiary care hospital within the Northwell Health System in New York, United States. Patients COVID-19 invasively mechanically ventilated patients in Medical Intensive Care Unit Settings. Methods TEG was monitored in COVID-19 critically ill patients. Patterns were reviewed to guide the development of a treatment protocol leveraging TEG parameters to select anticoagulant therapy. Three cases are reported to highlight TEG profiles that led to the development of the algorithm. Clinical trajectory and treatment decisions were retrospectively extracted from the Electronic Health Record with input from the intensivists. Anticoagulant use, laboratory and TEG values, and venous/arterial lower extremity (LE) ultrasound results were recorded. Main Results These cases demonstrate hypercoagulable TEG results despite prophylactic or therapeutic dosages of unfractionated heparin or low molecular weight heparin (LMHW). TEG surveillance identified functional fibrinogen and maximum amplitude in high risk patients with hyper-inflammatory markers. Anticoagulation assessment, TEG parameters, and LE ultrasound monitoring for venous and arterial thrombus were used to construct an algorithm to guide and escalate anticoagulant therapy. Conclusions TEG provides patient-specific evidence for hypercoagulable state in patients receiving all types of anticoagulant therapy. The proposed TEG algorithm guides anticoagulation management decisions to maintain or escalate anticoagulant dose and/or change choice of anticoagulant. A TEG algorithm may help negotiate the potential harm/benefit balance of full dose anticoagulation in COVID-19 critically ill patients, by allowing for a more individualized approach that goes beyond the review of activated partial thromboplastin time (aPTT) levels.

Coronavirus disease 2019 infection is associated with hypercoagulability and thrombotic risks which have prompted worldwide clinical trials investigating the best anticoagulation strategies to minimize thromboembolic risk while balancing risk of bleeding.

Autopsy findings in COVID-19 patients have demonstrated venous thromboembolic events (TE) in up to 58% of cases, diffuse alveolar damage, endothelial damage and pulmonary microthrombi. 1,2 SARS coronavirus 2 (SARS-CoV-2) cell entry causes a pro-inflammatory cascade through increased cytokines and angiotensin II effects following downregulation of angiotensin converting enzyme 2. 3, 4 This complex path of SARS-CoV2 infection involves an immuno-thrombotic effect leading to endothelial dysfunction and a vasculopathy on a multi-organ level. Elevated D-dimer and fibrinogen levels are associated with increased thrombosis despite routine thromboprophylactic dosing with either unfractionated heparin (UFH) or low molecular weight heparin (LMWH). [5] [6] [7] [8] Limited evidence if emerging regarding optimal thromboprophylaxis anticoagulant dosing however the thrombotic risk is clearly evident based on procoagulant parameters and clinical outcomes. 9 Our institution's standard of care had adopted prophylactic to intermediate dosing for DVT in hospitalized COVID -19 patients. 10 In the recently published multicenter trials REMAP-CAP, ACTIV-4a and ATTACC, therapeutic-dose anticoagulation with heparin in non-critically ill patients with COVID-19 increased survival to hospital discharge with reduced use of cardiovascular or respiratory organ support compared to the thromboprophylactic group. These benefits were not replicated in critically ill COVID-19 patients however the question still exists as to whether select ICU patient populations may benefit from therapeutic anticoagulation. 11, 12 A targeted approach to anticoagulation may help to identify those critically ill patients who will benefit from escalated anticoagulation. Published protocolized guides have been implemented in many healthcare institutions to address the growing concern for thrombotic complications in the critically ill. Some examples of such protocols were guided by d-dimer and Thromboelastography (TEG). 13, 14 Hranjec et al found increased risk for mechanical ventilation, acute kidney injury, dialysis and death in critically-ill COVID-19 patients managed without algorithm-TEG guidance compared to patients managed with such an algorithm. 14 TEG profiles consistently demonstrated extreme hypercoagulable states, while absent fibrinolysis coupled with elevated D-dimer has been predictive of TE and hemodialysis in COVID-19 critically-ill patients. 8, [15] [16] [17] [18] Viscoelastic testing has been used as a measure of viscosity and clot formation since the end of the 19 th century. The original viscometers and the early thromboelastograph were bedside monitors that utilized a "cup in pin" platform. The cup was filled with whole blood, while the motion of a pin inside the cup was measured as either the pin or the cup oscillated. The motion of the pin was then coupled to an oscillograph from which signature tracings evolved. The signature tracings have become well-described throughout the literature as diagnostic of certain disease states.

Platelet dysfunction, fibrinogen dysfunction and other hypocoagulable states are diagnosed by a certain tracing appearance. Less frequently adopted but equally important is the use of the viscoelastic test in the detection and identification of hypercoagulable states. Patients with a higher maximum amplitude (MA), or clot strength, immediately after non-cardiac surgery, may have a higher occurrence of thrombotic complications and perioperative myocardial infarction. 19 Kashuk et al showed that patients with a high MA in the surgical intensive care unit had higher incidence of TE postoperatively. 20 Gurbel and colleagues studied the intracoronary stent population and found that patients with a higher baseline MA prior to stent had a higher incidence of stent occlusion and ischemic events. 21, 22 These same investigators also studied platelet reactivity indices for 6 months after stent placement and found a correlation between higher MA and ischemic events throughout the study period. Many investigators have studied the high reactivity of platelets by using MA response to adenosine diphosphate (MA-ADP) in the Platelet Mapping ® assay. High MA-ADP has been associated with post-stent ischemic events. 23 Viscoelastic testing has evolved throughout many iterations. The original TEG tracing has a characteristic shape and output parameters. A typical tracing is shown in Figure 1 . The cup-in-pin technology of viscoelastic testing has been replaced with newer ultrasonic technology in a cartridge-based system, the TEG 6S®. The TEG 6S ® is a point-of-care instrument that uses such cartridge technology to measure the parameters of clot formation in 4 channels simultaneously. The test outputs that were once available by running 4 different cup-in-pin channels are now available from a single cartridge that houses 4 channels. The clinically relevant parameters that we used from these 4 channels are described in Table 1 . Table 3 , Figure 2G , 2H]. PaO2/FiO2 remained in the low 100s and progressive AKI led to dialysis by day 21. Unfortunately, the patient expired on day 22 due to multi-organ failure.

These cases are a sample of difficult decision-making in COVID19 critical care.

The incidence of TE and the persistence of elevated functional fibrinogen activity on TEG despite anticoagulation, prompted a multidisciplinary task force to generate a protocol to guide decision making around anticoagulation.

Hospitalized COVID-19 patients were placed on prophylactic anticoagulation with UFH or LMWH based on BMI and creatinine clearance as directed by our institutional protocol. It became apparent with TEG evaluation that a hallmark of the hypercoagulable state was an extremely high FF and Rapid TEG MA which also persisted despite large doses of anticoagulants and even anti-platelet agents. We 

Intensivists commonly need to balance clinical judgment with a paucity of evidence when addressing anticoagulation needs for critically ill COVID-19 patients. Of particular concern is the risk of harm from empiric anticoagulation versus the benefit of mitigating thromboembolism. A further concern is whether the conventionally used markers of adequate anticoagulation are misleading in some cases. We propose this TEG protocol as a guide to anticoagulation management in critically ill COVID-19 patients, however many gaps in our understanding of COVID-19 thrombotic risk and anti-thrombotic therapies still exist. Our next step is to retrospectively study outcomes of thrombotic events, major bleeding and mortality in critically ill COVID-19 patients However absent laboratory monitoring for enoxaparin was a study limitation and perhaps intermediate dose was insufficient to achieve a significant outcome.

Enoxaparin use is not routinely checked with anti-Xa level and target goals may vary.

Standard dosing of LMWH was associated with suboptimal anti-Xa levels in 30% of COVID-19 ward patients. 25 Despite meeting anti-Xa targets in ICU COVID-19 patients treated with higher-dose LMWH as thromboprophylaxis, TEG profiles remained hypercoagulable. 26 Argatroban, a direct inhibitor of free and clot-bound thrombin, works independent of antithrombin levels and may be a promising anticoagulant with antiinflammatory, antiviral, and anti-platelet properties. 27 In a cohort of ten ICU COVID-19 patients with confirmed thrombosis despite prophylactic dose LMWH, full dose heparin failed to achieve therapeutic anti-Xa levels which was attributed to laboratory evidence of antithrombin deficiency. For this reason, the anticoagulant was changed to argatroban which improved thrombotic complications in renal replacement and ECMO circuits. 28 Heparin resistance defined as requiring more than 35,000 units/day of UFH occurs in COVID-19 ICU patients raising the concern as to the optimal aPTT goal or monitoring parameter. 29 Antithrombin deficiency can result in heparin resistance in which case argatroban may be a better anticoagulant. TEG provides a viscoelastic assessment of thrombotic versus bleeding risk and may guide decisions around escalation versus maintaining anticoagulation. In the context of hypercoagulable TEG profiles without an overt bleeding risk, our algorithm may serve to select out critically ill patients for consideration of escalation to full dose anticoagulation with UFH or argatroban. Antiplatelet therapy with aspirin and/or clopidogrel are also considerations, particularly in the treatment of arterial thrombus. Fibrinolysis at 30 minutes (LY30) is another TEG parameter for consideration that we did not measure in our patient population. One report shows that complete lack of LY30 and d-dimer > 2,600 ng/mL, was associated with a venous TE rate of 50% compared to 0% in patients without either parameter. 18 33 Higher oxygenation improvements in COVID-19 patients treated with a regimen of tirofiban, acetylsalicylic acid, clopidogrel and fondaparinux was observed in a case-control study. 34 The anti-platelet agent, dipyridamole may also inhibit SARS-CoV-2 replication and have antiinflammatoryproperties. 35 

Hypercoagulable TEG profiles are observed in COVID-19 ICU patients. The proposed TEG algorithm serves as a guide to assess hypercoagulable states in COVID-19 ICU patients in a manner that addresses individual thrombosis profiles. Bleeding risks can also be monitored using TEG profiles. TEG provides objective, patient-specific evidence for the pathologic coagulation status in critically ill COVID-19 patients. Figure 1 . Thromboelastograph from TEG 6S® displaying four tracings of whole blood exposed to various agents and activators. Reaction (R) time is the time to the "split", the first detectable clot formation. The K time is the time to an amplitude of 20 mm. The alpha angle (α), is the angle between the horizontal axis of the R time and the tangent to the curve at the point where the amplitude is 20 mm wide. K time and alpha angle are parameters that measure kinetics of clot formation such as fibrinogen turnover. They have not been widely used in clinical diagnosis or algorithms. The maximal clot formation (MA) is the widest amplitude on the tracing, representing the clot strength based on platelet and fibrinogen interaction. When kaolin is the activator used in citrated (C) whole blood, this amplitude is referred to as citrated-kaolin MA (CK MA). CK (red) = citrated specimen with kaolin activator; CRT (purple) = Rapid TEG which tests a citrated specimen with tissue factor; CKH (green) = citrated specimen with kaolin and heparinase; CFF (blue) is a citrated specimen with tissue factor plus abciximab, a glycoprotein IIb/IIIa inhibitor that will remove platelet binding, thus the resultant amplitude represents fibrinogen function alone. 

Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

The science underlying COVID-19: Implications for the cardiovascular system

Cell entry mechanisms of SARS-CoV-2

High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prostpective cohort study

Thrombosis in hospitalized patients with COVID-19 in a New York City health system

Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence

Thromboelastography profiles of critically ill patients with coronavirus disease 2019

COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-Up: JACC State-of-the-Art Review

Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

ACTIV-4a Investigators

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

ATTACC Investigators

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

D-dimer-driven anticoagulation reduces mortality in intubated COVID-19 Patients: A cohort study with a propensity-matched analysis

Integral use of thromboelastography with platelet mapping to guide appropriate treatment, avoid complications, and improve survival of patients with coronavirus disease 2019-related coagulopathy

Thromboelastographic results and hypercoagulability syndrome in patients with coronavirus disease 2019 who are critically ill

Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis

Thromboelastography findings in critically ill COVID-19 patients

Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection

Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction

Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients

Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study

The link between heightened thrombogenicity and inflammation: Pre-procedure characterization of the patient at high risk for recurrent events after stenting

Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention, Is the current antiplatelet therapy adequate

Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION Randomized Clinical Trial

Thromboprophylaxis in COVID-19: Anti-FXathe missing factor?

Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit

Thrombin inhibition by argatroban: potential therapeutic benefits in COVID-19

Anticoagulation with argatroban in patients with acute antithrombin deficiency in severe COVID-19

Heparin resistance in COVID-19 patients in the intensive care unit

COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms

STudy of Alteplase for Respiratory failure in SARS-Cov2/COVID-19: Study design of the phase IIa STARS trial

The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19

The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome

Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19